ProCE Banner Activity

Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

Podcast Episodes

Audio podcast with highlights from a live webinar covering available clinical data and approved treatments for ROS1-altered TKI-naive advanced non-small-cell lung cancer (NSCLC). Listen to the experts review and discuss their perspectives and summarize clinical data in support of guideline-recommended first-line treatment approaches. 

Released: September 05, 2024

Expiration: September 04, 2025

Share

Faculty

Jessica J Lin

Jessica J Lin, MD

Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice Shaw

Alice Shaw, MD, PhD

Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol-Myers Squibb.

Bristol Myers Squibb

Disclosure

Primary Author

Jessica J Lin, MD

Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jessica J. Lin, MD: consultant/advisor/speaker: AnHeart Therapeutics, AstraZeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, C4 Therapeutics, Claim Therapeutics, Daiichi Sankyo, Elevation Oncology, Ellipses, Genentech, Hyku BioSciences, Merus, Mirtati Therapeutics, Novartis, Nuvalent, Pfizer, Regeneron, Takeda, Turing Point Therapeutics, Yuhan; researcher (paid to institution): Bayer, Elevation Oncology, Hengrui Therapeutics, Linnaeus Therapeutics, Neon Therapeutics, Novartis, Nuvalent, Pfizer, Roche, Relay Therapeutics, Turning Point Therapeutics; other (travel support): Merus, Pfizer.

Alice Shaw, MD, PhD

Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Alice Shaw, MD, PhD: employee (relationship has ended): Novartis.